Brooks Laboratories
- P/E
- 14.59
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 21.20%
- Debt to Equity
- 0.07
- EPS (TTM)
- ₹4.49
- Book Value
- ₹41.64
- Market Cap
- —
- P/E (TTM)
- 14.59
- P/B
- 1.57
- ROE
- 22.00%
- Dividend Yield
- 0.00%
- EBITDA
- ₹8.20 Cr
- 52W High
- ₹112.40
- 52W Low
- ₹36.30
- Day Range
- ₹64.17 – ₹70.09
- Volume
- 1,11,461
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Brooks Laboratories (this company) | ₹65.49 | 14.59 | ₹194 Cr | 1.57 | 0.00% | 22.00% | 21.20% | ₹83 Cr | ₹13 Cr |
| Median 8 companies | ₹1,587.70 | 37.20 | ₹1,25,337 Cr | 4.57 | 0.44% | 17.40% | 19.15% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 44
- Weak
- Returns, margins, earnings quality 22% weight
- Valuation
- 63
- Good
- Cheap vs sector & own history 24% weight
- Growth
- 27
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 80
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 78
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 53
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company is almost debt free.
- Company has delivered good profit growth of 26.6% CAGR over last 5 years
Weaknesses
5- The company has delivered a poor sales growth of 2.11% over past five years.
- Company has a low return on equity of -2.02% over last 3 years.
- Contingent liabilities of Rs.123 Cr.
- Earnings include an other income of Rs.13.0 Cr.
- Promoter holding has decreased over last 3 years: -11.0%
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 2 | 7 | 10 |
| Oscillators | Neutral | 1 | 7 | 1 |
| Moving Averages | Strong Bullish | 1 | 0 | 9 |
Oscillators
Neutral
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 55.42
- Neutral
- MACD (12,26,9)
- 0.29
- Bullish
- SMA (50)
- 62.62
- Bullish
- SMA (200)
- 63.20
- Bullish
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 5Y | +2.24% |
|---|---|
| 3Y | +10.93% |
| 1Y | +3.61% |
| TTM | −7.71% |
Net profit
| 5Y | Turned to profit |
|---|---|
| 3Y | Turned to profit |
| 1Y | Turned to profit |
| TTM | +550.74% |
Operating cash flow
| 5Y | +17.61% |
|---|---|
| 3Y | Turned positive |
| 1Y | +200.00% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 5Y | +6.84 pp |
|---|---|
| 3Y | +55.76 pp |
| 1Y | +17.78 pp |
| TTM | +6.48 pp |
Revenue by year
| Mar 2021 | ₹77.00 Cr |
|---|---|
| Mar 2022 | ₹91.00 Cr |
| Mar 2023 | ₹63.00 Cr |
| Mar 2024 | ₹79.00 Cr |
| Mar 2025 | ₹83.00 Cr |
| Mar 2026 | ₹86.00 Cr |
Net profit by year
| Mar 2021 | −₹19.00 Cr |
|---|---|
| Mar 2022 | −₹19.00 Cr |
| Mar 2023 | −₹31.00 Cr |
| Mar 2024 | −₹20.00 Cr |
| Mar 2025 | −₹10.00 Cr |
| Mar 2026 | ₹25.00 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15.7 | 24.32 | 21.75 | 17.72 | 17.93 | 20.79 | 20.52 | 23.32 | 25.51 | 23.45 | 16.57 | 20.21 | 22.96 |
| Expenses | 19.61 | 25.42 | 25.12 | 27.25 | 19.85 | 24.2 | 22.02 | 24.58 | 22.38 | 20.93 | 15.84 | 19.53 | 24.3 |
| Operating Profit | −3.91 | −1.1 | −3.37 | −9.53 | −1.92 | −3.41 | −1.5 | −1.26 | 3.13 | 2.52 | 0.73 | 0.68 | −1.34 |
| OPM % | −24.9% | −4.52% | −15.49% | −53.78% | −10.71% | −16.4% | −7.31% | −5.4% | 12.27% | 10.75% | 4.41% | 3.36% | −5.84% |
| Other Income | 0.05 | 0.09 | 0.16 | 0.65 | 0.07 | 0.2 | 0.03 | 0.62 | 7.15 | 6.13 | 5.32 | 1.35 | 0.18 |
| Interest | 0.17 | 0.19 | 0.21 | 0.27 | 0.16 | 0.32 | 0.28 | 0.26 | 0.3 | 0.28 | 0.16 | 0.09 | 0.21 |
| Depreciation | 0.44 | 0.44 | 0.43 | 0.46 | 0.4 | 0.43 | 0.38 | 0.39 | 0.39 | 0.39 | 0.39 | 0.41 | 0.42 |
| PBT | −4.47 | −1.64 | −3.85 | −9.61 | −2.41 | −3.96 | −2.13 | −1.29 | 9.59 | 7.98 | 5.5 | 1.53 | −1.79 |
| Tax % | 0% | 0% | 0.78% | 0% | 0% | 0% | 0% | 13.95% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | −4.47 | −1.64 | −3.88 | −9.61 | −2.41 | −3.96 | −2.13 | −1.46 | 9.58 | 7.98 | 5.5 | 1.52 | −1.79 |
| EPS (₹) | −1.71 | −0.62 | −1.48 | −3.66 | −0.92 | −1.51 | −0.81 | −0.5 | 3.25 | 2.71 | 1.87 | 0.52 | −0.61 |
Profit & Loss
₹ Cr| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 77 | 91 | 63 | 79 | 83 | 86 | 83 |
| Expenses | 77 | 105 | 93 | 97 | 91 | 79 | 81 |
| Operating Profit | 1 | −14 | −30 | −18 | −8 | 7 | 3 |
| OPM % | 0.7% | −16% | −47% | −22% | −10% | 8% | 3.1% |
| Other Income | 1 | 1 | 1 | 1 | 1 | 20 | 13 |
| Interest | 3 | 3 | 2 | 1 | 1 | 1 | 1 |
| Depreciation | 7 | 7 | 7 | 2 | 2 | 2 | 2 |
| PBT | −9 | −24 | −38 | −20 | −10 | 25 | 13 |
| Tax % | 115% | −19% | −19% | 0% | 2% | 0% | — |
| Net Profit | −19 | −19 | −31 | −20 | −10 | 25 | 13 |
| EPS (₹) | −7.4 | −4.31 | −7.97 | −7.46 | −3.38 | 8.34 | 4.49 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity Capital | 25 | 25 | 25 | 26 | 29 | 29 |
| Reserves | 54 | 63 | 49 | 39 | 69 | 93 |
| Borrowings | 31 | 25 | 7 | 6 | 8 | 9 |
| Other Liabilities | 52 | 83 | 29 | 19 | 18 | 17 |
| Total Liabilities | 162 | 196 | 110 | 90 | 124 | 148 |
| Fixed Assets | 108 | 110 | 15 | 14 | 14 | 15 |
| CWIP | 1 | 15 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 64 | 43 | 74 | 92 |
| Other Assets | 54 | 71 | 31 | 34 | 36 | 40 |
| Total Assets | 162 | 196 | 110 | 90 | 124 | 148 |
Cash Flow
₹ Cr| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | 4 | −37 | −14 | −10 | 3 | 9 |
| Investing | −5 | −25 | 0 | 0 | −45 | −3 |
| Financing | 1 | 64 | 11 | 10 | 42 | 0 |
| Net Cash Flow | 0 | 2 | −3 | 0 | 0 | 7 |
| Free Cash Flow | −1 | −62 | −15 | −10 | 2 | 6 |
| CFO/EBITDA | 1,519 | 261 | 48 | 56 | −26 | 131 |
Ratios
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor Days | 65 | 71 | 74 | 75 | 88 | 69 |
| Inventory Days | 178 | 157 | 80 | 60 | 61 | 77 |
| Days Payable | 233 | 159 | 165 | 97 | 90 | 80 |
| Cash Conversion Cycle | 9 | 68 | −12 | 38 | 59 | 66 |
| Working Capital Days | −85 | 34 | −37 | 34 | 43 | 34 |
| ROCE % | — | −16% | −30% | −25% | −10% | 21% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Brooks Laboratories insights
67 extracted metrics across FY10–FY27.
Documents
- 13 Aug 2026
- 29 May 2026
- 13 Aug 2025
- 11 Nov 2025
- 7 Nov 2024
- 31 Oct 2023
- 11 Nov 2022
- 25 Mar 2021
- General announcements 3 Nov 2026
- General announcements 13 Oct 2026
Frequently Asked Questions about Brooks Laboratories
What does Brooks Laboratories Ltd do?
Where is Brooks Laboratories Ltd (BROOKS) listed?
Which sector does Brooks Laboratories Ltd belong to?
What is the PE ratio of Brooks Laboratories Ltd?
What is the 52-week high and low of Brooks Laboratories Ltd?
What is the Return on Equity (ROE) of Brooks Laboratories Ltd?
Company Information
Incorporated in 2002, Brooks Laboratories Ltd is a pharmaceutical company working on contract basis catering to the critical care segment
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/BROOKS.md for Brooks Laboratories Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.